B. Zanker

发表

Tumor necrosis factor-α, interleukin-1β, and interleukin-6 expression in inflammatory bowel disease

T. Strom, G. Walz, D. Antonioli, 1992, Digestive Diseases and Sciences.

The immunosuppressive effects of verapamil upon mitogen activated and allo-antigen inducible human cytotoxic T-lymphocytes.

T. Strom, B. Zanker, H. Köhler, 1994, International journal of immunopharmacology.

Evidence that glucocorticosteroids block expression of the human interleukin-6 gene by accessory cells.

T. Strom, G. Walz, B. Zanker, 1990, Transplantation.

Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma.

T. Strom, W. Almawi, B. Zanker, 1991, Journal of immunology.

Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease.

T. Strom, G. Walz, D. Antonioli, 1992, Digestive diseases and sciences.

Multidrug resistance gene MDR1 expression: a gene transfection in vitro model and clinical analysis in cyclosporine-treated patients rejecting their renal grafts.

B. Zanker, W. Land, C. Barth, 1997, Transplantation proceedings.

Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation.

T. Strom, G. Walz, B. Zanker, 1989, Proceedings of the National Academy of Sciences of the United States of America.

A kinetic analysis of the effects of interleukin-2 diphtheria toxin fusion protein upon activated T cells.

T. Strom, G. Walz, B. Zanker, 1990, Transplantation.

EVIDENCE THAT FUNCTIONAL DELETION OF DONOR‐REACTIVE T LYMPHOCYTES IN KIDNEY ALLOGRAFT RECIPIENTS CAN OCCUR AT THE LEVEL OF CYTOTOXIC T CELLS, IL‐2-PRODUCING T CELLS, OR BOTH

D. Kabelitz, B. Zanker, H. Wagner, 1993, Transplantation.

SELECTIVE REDUCTION OF DONOR‐SPECIFIC CYTOTOXIC T LYMPHOCYTE PRECURSORS IN PATIENTS WITH A WELL‐FUNCTIONING KIDNEY ALLOGRAFT

W. Herzog, D. Kabelitz, C. Huber, 1987, Transplantation.

Human Cytotoxic T Lymphocytes

W. Herzog, D. Kabelitz, B. Zanker, 1985, Scandinavian journal of immunology.

Low zone desensitization: a stimulus-specific control mechanism of cell response. Investigations on anaphylatoxin-induced platelet secretion

D. Bitter‐Suermann, B. Zanker, U. Hadding, 1982, The Journal of experimental medicine.

LOW ZONE DESENSITIZATION: A STIMULUS-SPECIFI C CONTROL MECHANISM OF CELL RESPONSE Investigations on Anaphylatoxin-in duced

D. Bitter‐Suermann, B. Zanker, U. Hadding, 1982 .

Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression: first-3-months analysis of efficacy and safety in two cohorts of renal allograft recipients.

B. Zanker, W. Land, U. Rothenpieler, 1998, Transplantation.

Physiologic signaling in normal human T-cells: mRNA phenotyping by northern blot analysis and reverse transcription-polymerase chain reaction.

M. Suthanthiran, T. Strom, G. Walz, 1990, Cellular immunology.

Mycophenolate mofetil in patients with acute renal failure: evidence of metabolite (MPAG) accumulation and removal by dialysis

B. Zanker, W. Land, H. Schneeberger, 1996, Transplant international : official journal of the European Society for Organ Transplantation.

Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation.

B. Zanker, J. Morales, Y. Vanrenterghem, 1998, Transplantation proceedings.

Transcriptional modulation of human IL-6 gene expression by verapamil.

T. Strom, G. Walz, B. Zanker, 1990, Journal of immunology.

Nephrotoxicity-free, mycophenolate mofetil-based induction/maintenance immunosuppression in elderly recipients of renal allografts from elderly cadaveric donors.

B. Zanker, W. Land, M. Stangl, 2000, Transplantation proceedings.

Quantitative assessment of interleukin-2-producing alloreactive human T cells by limiting dilution analysis.

D. Kabelitz, B. Zanker, H. Wagner, 1988, Journal of immunological methods.

Possible association of the immunosuppressive and B cell lymphoma-promoting properties of cyclosporine.

M. Suthanthiran, T. Strom, G. Walz, 1990, Transplantation.

[The immunobiology of transplant rejection and its pharmacological modification].

T. Strom, B. Zanker, H. Köhler, 2008, Deutsche medizinische Wochenschrift.

Hyperimmunoglobulin prophylaxis, monitoring and preemptive ganciclovir treatment eliminate the risk of CMV infection to improve patient and renal allograft survival

B. Zanker, W. Land, W. Illner, 2000, Transplant international : official journal of the European Society for Organ Transplantation.

T. Strom, G. Walz, B. Zanker, 1989, Transplantation.

Low systemic exposure to tacrolimus correlates with acute rejection.

J. Hooff, B. Zanker, J. Morales, 1999, Transplantation proceedings.

Restricted T cell V beta repertoire in renal allografts during acute and chronic rejection.

B. Zanker, C. Barth, C. Baldamus, 1996, Kidney international.

Tacrolimus as a primary immunosuppressive therapy in cadaveric renal transplantation: five years' experience at a single center.

B. Zanker, W. Land, U. Rothenpieler, 1998, Transplantation proceedings.

Aggressive treatment of the first acute rejection episode using first‐line anti‐lymphocytic preparation reduces further acute rejection episodes after human kidney transplantation

B. Zanker, W. Land, M. Stangl, 1998 .

Mycophenolate mofetil monotherapy: an example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients.

B. Zanker, W. Land, C. Keunecke, 2000, Transplantation proceedings.

[Baclofen intoxication in chronic hemodialysis and kidney transplantation].

B. Zanker, K. Meyer zum Büschenfelde, H. Köhler, 2008, Deutsche medizinische Wochenschrift.

and chronic rejection

B. Zanker, C. Barth, J. Stachowski, 1996 .

Expression of the multidrug resistance gene MDR-1 in peripheral blood mononuclear cells from cyclosporine-treated renal transplant recipients rejecting their graft.

B. Zanker, C. Barth, C. Baldamus, 1995, Transplantation proceedings.

Influence of macrophage activation on the synthesis of complement components C2, C3, C4.

H. Hartung, D. Bitter‐Suermann, B. Zanker, 1982, Advances in experimental medicine and biology.

Interleukin-7 (IL-7) and its effect on the expression of the intercellular adhesion molecule (ICAM-1) in T cells.

T. Strom, B. Zanker, C. Barth, 1991, Transplantation proceedings.

Cyclosphorine sensitivity in renal transplant patients. Quantitative assessment of interleukin-2-producing alloreactive helper T cells by limiting dilution analysis.

D. Kabelitz, B. Zanker, H. Wagner, 1988, Transplantation.

An inherited deficiency of the third component of complement, C3, in guinea pigs

J. Gordon, D. Bitter‐Suermann, B. Zanker, 1986, European journal of immunology.

Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients.

J. Squifflet, B. Zanker, J. Morales, 1998, Transplantation proceedings.

C3a induced activation and stimulus specific reversible desensitization of guinea pig platelets.

D. Bitter‐Suermann, B. Zanker, H. Rasokat, 1982, Agents and actions. Supplements.

Verapamil selectively inhibits expression of interleukin-2 messenger RNA in mitogen activated mononuclear blood cells.

T. Strom, G. Walz, B. Zanker, 1989, Transplantation proceedings.

Aggressive treatment of the first acute rejection episode using first-line anti-lymphocytic preparation reduces further acute rejection episodes after human kidney transplantation

B. Zanker, W. Land, M. Stangl, 1998, Transplant international : official journal of the European Society for Organ Transplantation.

The role of interleukin-6 in mitogenic T-cell activation: detection of interleukin-2 heteronuclear RNA by polymerase chain reaction.

M. Suthanthiran, T. Strom, G. Walz, 1991, Cellular immunology.